AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Background Enthesitis and dactylitis are associated with greater disease activity reduced quality of life. Results from the phase 3 randomized, placebo-controlled KEEPsAKE 1 2 studies ( NCT03675308 ; NCT03671148 ) risankizumab in active PsA showed resolution enthesitis 150 mg vs placebo at week 24. Objectives This post hoc analysis evaluated improvements patient-reported outcomes (PROs) among patients who had (n=444), (n=188), or both (n=128) baseline achieved enthesitis, dactylitis, blinded weeks 0, 4, 16, open-label every 12 thereafter. Methods Assessments included achievement minimal clinically important differences (MCID) pain (≥10-mm decrease on visual analog scale), Health Assessment Questionnaire-Disability Index (HAQ-DI; ≥0.35-unit decrease), Functional Chronic Illness Therapy (FACIT-Fatigue; ≥4-point increase). Nonresponder imputation (with multiple for COVID-19–related missing data 24) was used. Many 24|week 52 also MCID (66.4%|71.4%), HAQ-DI (58.2%|63.4%), FACIT-Fatigue (59.0%|72.1%). pain, (72.2%|81.7%), (56.3%|66.2%), (67.7%|69.9%). (82.1%|86.4%) (66.7%|69.2%), (71.4%|74.6%). PRO results did not achieve and/or will be presented. Conclusion Majority reported disability, fatigue. Acknowledgements AbbVie authors thank participated study all investigators their contributions. Medical writing assistance, funded by AbbVie, provided Lisa M Pitchford, PhD, JB Ashtin. Disclosure Interests Shawn Kwatra Consultant of: Aslan Pharmaceuticals, Arcutis, Celldex, Galderma, Genzada Incyte, Johnson & Johnson, Novartis, Pfizer, Regeneron, Sanofi., Grant/research support from: Saakshi Khattri Speakers bureau: Eli Lilly, Janssen, UCB, Bristol Myers Squibb, LEO Pharma, Ahmad Amin Amgen, Dermavant, Sanofi/Genzyme, Ran Liu Shareholder Employee Byron Padilla Ahmed M. Soliman Blair Kaplan Dennis McGonagle Pfizer., BMS, Celgene.